on patients throughout the US and Puerto Rico.
AstraZeneca has been named one of the "100 Best Companies for Working
Mothers" by Working Mother magazine and is the only large pharmaceutical
company named to FORTUNE magazine's 2007 list of "100 Best Companies to
Work For." In 2006, for the fifth consecutive year, Science magazine named
AstraZeneca a "Top Employer" on its ranking of the world's most respected
biopharmaceutical employers.
For more information about AstraZeneca, please visit:
http://www.astrazeneca-us.com
Notes To Editors:
-- AstraZeneca submitted a proposed pediatric study request to the United
States Food and Drugs Administration (FDA) in 1999, in response to
which the FDA issued a Written Request, which outlined four clinical
studies to investigate the potential health benefits of ARIMIDEX in two
pediatric conditions: gynecomastia in pubertal boys and precocious
puberty in girls with McCune-Albright Syndrome (MAS). The purpose of
these studies was to examine the safety, efficacy and pharmacokinetics
of ARIMIDEX in these pediatric populations where an unmet need
currently exists.
-- The outcomes of the studies were that:
-- Study 0006 (gynecomastia) did not show any evidence for an effect of
ARIMIDEX versus placebo in the treatment of moderate-to-severe
pubertal gynecomastia;
-- Study 0046 (McCune Albright syndrome) suggested that ARIMIDEX does
not demonstrate a clear benefit in the treatment of precocious
puberty in the heterogeneous population of girls with the rare
disease of MAS. There was no observed benefit in terms of reducing
the frequency of vaginal bleeding, decreasing the rate of increase
in bone age or reducing growth rate in the overall group.
'/>"/>SOURCE AstraZeneca Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
AstraZeneca Leads Local Walking Movement2.
AstraZeneca Joins Local Walking Movement3.
Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs4.
Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca5.
AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year6.
AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance7.
NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development8.
Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca9.
Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval10.
AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts11.
Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store